Gilead Sciences Inc patents expiration
1. Biktarvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US9216996 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(9 years from now) | |
| US9732092 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(9 years from now) | |
| US9708342 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| US10385067 | GILEAD SCIENCES INC | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
Jun, 2035
(11 years from now) | |
| US11744802 | GILEAD SCIENCES INC | Therapeutic compositions for treatment of human immunodeficiency virus |
Nov, 2036
(12 years from now) | |
| US10548846 | GILEAD SCIENCES INC | Therapeutic compositions for treatment of human immunodeficiency virus |
Nov, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
| M(M-82) | Feb 24, 2024 |
| Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
| Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
| New Patient Population(NPP) | Jun 18, 2022 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
BIKTARVY family patents
2. Complera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
| US7067522 | GILEAD SCIENCES INC | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) | |
| US6838464 | GILEAD SCIENCES INC | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(3 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US8080551 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(1 year, 14 days ago) | |
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US8101629 | GILEAD SCIENCES INC | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 8 months ago) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
|
US8716264 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
| US8841310 | GILEAD SCIENCES INC | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Dec, 2025
(1 year, 7 months from now) | |
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 13, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
COMPLERA family patents
3. Descovy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Patient Population(NPP) | Sep 28, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
DESCOVY family patents
4. Epclusa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| US11707479 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
|
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
|
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
|
US11707479 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| M(M-264) | Jul 14, 2023 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| M(M-277) | Apr 27, 2025 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Strength(NS) | Mar 19, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL
EPCLUSA family patents
5. Genvoya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(2 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
| US7800788 | GILEAD SCIENCES INC | Upright image processing apparatus with pivotable image reading portion |
Feb, 2022
(2 years ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
|
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
|
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(6 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
GENVOYA family patents
6. Harvoni patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8088368 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8822430 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| US10039779 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
| US8273341 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US8841278 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
| US9511056 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(6 years from now) | |
|
US8822430 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US8273341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US8088368 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US8841278 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US9511056 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(6 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
| US10456414 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
|
US9393256 (Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(8 years from now) | |
|
US10039779 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks
Dosage: PELLETS;ORAL; TABLET;ORAL
HARVONI family patents
7. Odefsey patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US7067522 | GILEAD SCIENCES INC | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) | |
| US6838464 | GILEAD SCIENCES INC | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(3 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US8080551 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(1 year, 14 days ago) | |
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(11 months from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
| US8101629 | GILEAD SCIENCES INC | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 8 months ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-207) | Aug 21, 2020 |
| M(M-206) | Aug 21, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
ODEFSEY family patents
8. Sovaldi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
| US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
|
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin; For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL
SOVALDI family patents
9. Stribild patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(2 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
|
US8716264 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
|
US9891239 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(6 years from now) | |
|
US8633219 (Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(6 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-704) | Dec 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
| New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
STRIBILD family patents
10. Sunlenca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(9 years from now) | |
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(13 years from now) | |
| US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: SOLUTION;SUBCUTANEOUS; TABLET;ORAL
SUNLENCA family patents
11. Tybost patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(5 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
TYBOST family patents
12. Veklury patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(4 years from now) | |
| USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(4 years from now) | |
| US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(5 years from now) | |
| US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(7 years from now) | |
| US11492353 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(7 years from now) | |
| US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(11 years from now) | |
| US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(12 years from now) | |
| US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(12 years from now) | |
| US11382926 | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(12 years from now) | |
| US11266681 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(14 years from now) | |
| US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(14 years from now) | |
| US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and ...
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
VEKLURY family patents
13. Vemlidy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 17, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-255) | Feb 04, 2023 |
| M(M-266) | Aug 22, 2023 |
| New Product(NP) | Nov 11, 2019 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older
Dosage: TABLET;ORAL
VEMLIDY family patents
14. Viread patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-569) | Aug 11, 2011 |
| M(M-128) | Jul 24, 2016 |
| M(M-95) | Oct 01, 2013 |
| Pediatric Exclusivity(PED) | Apr 01, 2014 |
| New Patient Population(NPP) | Aug 16, 2015 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Treatment: Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older; Treatment of hiv
Dosage: TABLET;ORAL; POWDER;ORAL
VIREAD family patents
15. Vitekta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(2 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220 (Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | |
|
US7635704 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
|
US8981103 (Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
Drugs and Companies using ELVITEGRAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
VITEKTA family patents
16. Vosevi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9585906 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US9868745 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US9296782 | GILEAD SCIENCES INC | Inhibitors of hepatitis C virus |
Jul, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957046 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
| US11338007 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(13 years from now) | |
| US10912814 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(13 years from now) | |
|
US11338007 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of a...
Dosage: TABLET;ORAL
VOSEVI family patents
17. Zydelig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6800620 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US8492389 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US8637533 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US8138195 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US6949535 | GILEAD SCIENCES INC | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(1 year, 3 months from now) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(1 year, 17 days from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(1 year, 17 days from now) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(1 year, 2 months from now) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lympho...
Dosage: TABLET;ORAL
ZYDELIG family patents